---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090747"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2026-08-17T20:05:37+00:00"
generated_at: "2026-08-17T20:08:12.738991+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# ENDRA to merge with Noble Africa, rename to Noble Africa Inc.; Q2 net income $160K

## Summary
- Merger with Noble Africa to rename ENDRA to Noble Africa Inc.; close expected Q4 2026.
- Private placement of ~$50M gross proceeds with institutional investors and ASP Isotopes, concurrent with merger close.
- Q2 2026 net income $160K vs net loss $1.2M in Q2 2025; cash $1.7M, restricted cash $3.8M, digital asset treasury $1.9M.
- Completed $3.8M private placement in May 2026; R&D expenses down 39%, sales & marketing down 92% YoY.
- Operating expenses $1.5M vs $1.3M; includes $542K non-cash stock comp vs $89K.

## SEC filing metadata
- accession: 0001213900-26-090747
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2026-08-17T20:05:37+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/0001213900-26-090747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/ea0302156-8k425_endra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090747
- JSON: https://secwatch.observer/filing/0001213900-26-090747.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.